Last Update 03 Mar 26

Fair value Increased 2.54%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins.

Analyst Commentary

Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.

Bullish Takeaways

Bullish analysts are lifting price targets into the DKK 2,400 to DKK 2,500 range and around US$40 to US$41.50, reflecting greater confidence in Genmab's longer term earnings power and valuation support at higher multiples.
Some models have been updated after the 2025 earnings report, with analysts comfortable maintaining positive ratings while refining their assumptions for revenue growth and cash generation.
Several bullish views highlight that recent acquisitions are seen as reducing terminal value risk and potentially smoothing the impact of the expected Darzalex royalty decline around 2029.
Analysts describing a "catalyst rich" 2026 see multiple data and regulatory events that, if successful, could support a stronger growth profile and justify the higher fair value assumptions now built into their targets.

Bearish Takeaways

More cautious analysts are trimming near term Epkinly estimates and resetting price targets, indicating concern that execution on key assets may fall short of earlier forecasts in the next few years.
Equal Weight views with lower price targets around US$34 highlight uncertainty over how quickly newly acquired assets, such as petosemtamab, can scale to offset pressure from maturing royalty streams.
Across the coverage, there is a focus on 2026 as a heavy catalyst year, which introduces event risk if clinical or commercial milestones do not meet expectations already reflected in current valuation frameworks.
Some research also points to the need for tighter execution on margins and product ramp ups, suggesting that any missteps could limit upside relative to the higher price targets set by bullish analysts.

What's in the News

Genmab issued 2026 guidance, expecting revenue of US$4.1b to US$4.4b compared to US$3.7b in 2025, with projected operating profit of US$0.9b to US$1.4b compared to US$1.3b in 2025. The company pointed to contributions from royalties on DARZALEX and Kesimpta, net product sales and collaboration revenue (company guidance).
Topline Phase 3 EPCORE DLBCL-1 results for epcoritamab in relapsed or refractory diffuse large B cell lymphoma showed an improvement in progression free survival versus comparator regimens, along with higher complete response rates and longer duration of response. Overall survival did not reach statistical significance, and Genmab and AbbVie plan to discuss next steps with regulators (company announcement).
Genmab announced updated data across several arms of the EPCORE CLL-1 trial in Richter transformation and EPCORE NHL-2 and DLBCL-3 in lymphoma. The company reported overall response and complete response rates alongside detailed safety profiles for epcoritamab as monotherapy and in combinations, with presentations at the American Society of Hematology 2025 meeting (company announcement).
The company decided to discontinue further clinical development of acasunlimab after assessing the competitive setting and will concentrate resources on late stage programs including EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, consistent with its portfolio prioritization approach (company announcement).
Genmab entered a partnership with Anthropic to deploy Claude powered AI tools across research and development and clinical operations. The initiative aims to speed up data processing, analysis and documentation within defined guardrails and human oversight as its late stage antibody pipeline expands (company announcement, Reuters).

Valuation Changes

Fair Value: DKK 2,182.25 to DKK 2,237.63, a modest uplift in the analyst fair value estimate.
Discount Rate: 5.30% to 5.82%, indicating a slightly higher required return in the updated model.
Revenue Growth: 13.68% to 18.64%, with analysts now assuming a higher long term growth rate for sales in their forecasts.
Net Profit Margin: 39.70% to 29.42%, reflecting more cautious assumptions on profitability even as growth expectations rise.
Future P/E: 10.09x to 12.71x, pointing to a higher valuation multiple being used for Genmab in the refreshed analysis.

12 views

Key Takeaways

Robust pipeline, global expansion, and independent product launches position Genmab for significant growth and improved competitive standing in targeted biologic therapies.
Strong recurring royalties and disciplined investment support stable cash flow, financial flexibility, and sustainable long-term earnings growth with diversified portfolio risk.
Genmab faces pressure from drug pricing, dependency on major partnerships, regulatory and pipeline risks, and intensifying competition threatening future growth and profitability.

Catalysts

About Genmab

A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.What are the underlying business or industry changes driving this perspective?

Strong late-stage pipeline progress-including positive Phase III results for epcoritamab (EPKINLY) and expansion of Rina-S programs-positions Genmab to benefit from the growing global burden of cancer and rising demand for innovative biologic therapies, supporting significant future revenue and earnings growth.
Continued advancement of innovative antibody and bispecific therapeutics leverages breakthroughs in precision medicine, likely increasing Genmab's competitive positioning and addressable market as healthcare systems prioritize targeted, personalized treatments, positively impacting long-term revenue trajectories.
Rapid international expansion and successful independent launches of EPKINLY and Tivdak (including in Europe and Japan) demonstrate Genmab's ability to capture a greater share of global healthcare spending, widening its revenue base and ultimately supporting higher operating margins as scale efficiencies improve.
Strong recurring royalty streams from established partnered products (such as DARZALEX) and a rising contribution from wholly owned product sales underpin stable, predictable cash flows, providing financial flexibility for pipeline investment and margin expansion.
Ongoing investment in commercialization infrastructure and disciplined R&D execution-backed by a robust cash position-set the stage for sustainable earnings growth as new products are introduced, markets expand, and portfolio risk becomes increasingly diversified.

Genmab Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Genmab's revenue will grow by 11.8% annually over the next 3 years.
Analysts assume that profit margins will shrink from 37.6% today to 35.2% in 3 years time.
Analysts expect earnings to reach $1.8 billion (and earnings per share of $28.16) by about September 2028, up from $1.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.2 billion in earnings, and the most bearish expecting $1.4 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 14.6x on those 2028 earnings, up from 12.2x today. This future PE is greater than the current PE for the GB Biotechs industry at 12.2x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 4.92%, as per the Simply Wall St company report.

Genmab Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Intensifying drug pricing pressures and tightened healthcare budgets in key markets (US, Europe) could constrain Genmab's pricing power and reimbursement access, which may slow future revenue and net margin growth despite the company's recent commercialization successes and strong sales momentum.
Overreliance on significant partnered assets, particularly DARZALEX (a key royalty driver), exposes Genmab to risks of renegotiated terms, royalty rate reductions, or even loss of rights, potentially leading to revenue volatility or future earnings declines as peak sales plateau or biosimilar competition emerges.
Regulatory risks-including heightened scrutiny, changing FDA review processes (noted market "chaos" at the FDA), and the possibility of delayed or denied approvals-pose a threat to pipeline advancement timelines, which could delay commercialization and revenue recognition for late-stage assets like Rina-S and EPKINLY in new indications.
Pipeline execution risk remains, as seen with the discontinuation of at least two HexaBody platform assets in 2025; if other pipeline programs also fail to differentiate or meet clinical endpoints, Genmab could face reduced R&D ROI, impairments, or stunted long-term growth in revenue and earnings.
Growing competition-both from other CD20 bispecifics (e.g., Roche's mosunetuzumab) and from emerging modalities like ADCs and next-generation immunotherapies-could erode Genmab's first-mover advantages, limit future market share, and pressure both future revenue trajectories and sustainable net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of DKK1941.888 for Genmab based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK2650.0, and the most bearish reporting a price target of just DKK1000.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $5.1 billion, earnings will come to $1.8 billion, and it would be trading on a PE ratio of 14.6x, assuming you use a discount rate of 4.9%.
Given the current share price of DKK1737.0, the analyst price target of DKK1941.89 is 10.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Genmab?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain